| Issue Date | Title | Author(s) |
| 81 | 2007 | A study of multiple drug resistance mechanisms improved against Bortezomib on multiple myeloma cell lines in vitro | Uyuklu, Tolga; Ural, A. Uğur; Sarper, Metal; Avcu, Ferit; Baran, Yusuf ; Elçi, Pınar; Akar, Nejat |
| 82 | Oct-2010 | Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells | Kosova, Buket; Tezcanlı, Burçin; Ekiz, Hüseyin Atakan ; Çakır, Zeynep; Selvi, Nur; Dalmızrak, Ayşegül; Yandım, Melis Kartal; Gündüz, Ufuk; Baran, Yusuf |
| 83 | 2020 | Synergistic apoptotic effects of bortezomib and methylstat on multiple myeloma cells | Kaci, Fatma Necmiye; Kiraz, Yağmur ; Çekdemir, Demet; Baran, Yusuf |
| 84 | Jan-2017 | Synthesis, cytotoxic and antimicrobial activities of novel cobalt and zinc complexes of benzimidazole derivatives | Apohan, Elif; Yılmaz, Ülkü; Yılmaz, Özgür; Serindağ, Ayfer; Küçükbay, Hasan; Yeşilada, Özfer; Baran, Yusuf |
| 85 | Jan-2016 | T cells in tumor microenvironment | Kiraz, Yağmur ; Baran, Yusuf ; Nalbant, Ayten |
| 86 | Mar-2015 | Targeting FoxM1 transcription factor in T-cell acute lymphoblastic leukemia cell line | Tüfekçi, Özlem; Kartal Yandım, Melis; Ören, Hale; İrken, Gülersu; Baran, Yusuf |
| 87 | Oct-2011 | Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation | Baran, Yusuf ; Bielawski, Jacek; Gündüz, Ufuk; Öğretmen, Besim |
| 88 | 2014 | Targeting sphingosine kinase-1/spingosine-1-phosphate receptor 2 signalling pathway to overcome T315I mutation in 32DCL3 cells | Adan Gökbulut, Aysun ; Öğretmen, Besim; Baran, Yusuf |
| 89 | Oct-2010 | Therapeutic applications of bioactive sphingolipids in hematological malignancies | Ekiz, Hüseyin Atakan ; Baran, Yusuf |
| 90 | May-2014 | Therapeutic potential of apigenin, a plant flavonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells | Solmaz, Soner; Adan Gökbulut, Aysun ; Çinçin, Zeynep Birsu; Özdoğu, Hakan; Boğa, Can; Çakmakoğlu, Bedia; Kozanoğlu, İlknur; Baran, Yusuf |
| 91 | 2014 | Therapeutic potential of fisetin, vitexin and hesperetin on chronic myeloid leukemia cells | Adan Gökbulut, Aysun ; Baran, Yusuf |
| 92 | 2023 | Therapeutic potential of luteolin on cancer | Çetinkaya, Melisa; Baran, Yusuf |
| 93 | Jan-2013 | Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer | Kartal Yandım, Melis; Apohan, Elif; Baran, Yusuf |
| 94 | 2020 | Therapeutic Potentials of Inhibition of Jumonji C Domain-containing Demethylases in Acute Myeloid Leukemia | Koca, Duygu; Hastar, Nurcan; Engür, Selin; Kiraz, Yağmur ; Ulu, Gizem Tuğçe ; Çekdemir, Demet; Baran, Yusuf |
| 95 | Dec-2015 | An update on molecular biology and drug resistance mechanisms of multiple myeloma | Mutlu, Pelin; Kiraz, Yağmur ; Gündüz, Ufuk; Baran, Yusuf |
| 96 | Jan-2014 | An update on molecular biology of thyroid cancers | Ömür, Özgür; Baran, Yusuf |
| 97 | Dec-2007 | Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance | Baran, Yusuf ; Gür, Bala; Kaya, Pelin; Ural, Ali Uğur; Avcu, Ferit; Gündüz, Ufuk |
| 98 | 2014 | Use of microRNAs in personalized medicine | Avcı, Çığır Biray; Baran, Yusuf |
| 99 | 2024 | X. Eğitim çalıştayı raporu | Tanoğlu, Gamze ; Özcan Gönülal, Yasemin ; Baran, Yusuf ; Yürüm, Ozan Raşit; Örün, Özgür; Daver, İlker; Gündüz, Umut Baran |
